GSK plc (LON:GSK - Get Free Report)'s share price crossed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of GBX 1,444 ($18.73) and traded as high as GBX 1,523.50 ($19.76). GSK shares last traded at GBX 1,490 ($19.32), with a volume of 10,344,893 shares.
Analyst Ratings Changes
Several research analysts recently weighed in on GSK shares. Berenberg Bank reduced their price target on GSK from GBX 1,820 ($23.60) to GBX 1,600 ($20.75) and set a "buy" rating for the company in a research report on Friday, November 29th. JPMorgan Chase & Co. reaffirmed an "underweight" rating on shares of GSK in a research note on Tuesday, January 7th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, GSK has an average rating of "Moderate Buy" and a consensus target price of GBX 1,805.83 ($23.42).
Get Our Latest Research Report on GSK
GSK Stock Down 1.7 %
The business has a 50-day moving average price of GBX 1,418.60 and a 200-day moving average price of GBX 1,444. The stock has a market cap of £60.46 billion, a PE ratio of 24.07, a price-to-earnings-growth ratio of 1.24 and a beta of 0.31. The company has a current ratio of 0.81, a quick ratio of 0.73 and a debt-to-equity ratio of 114.64.
GSK (LON:GSK - Get Free Report) last posted its quarterly earnings data on Wednesday, February 5th. The company reported GBX 23.20 ($0.30) earnings per share (EPS) for the quarter. GSK had a net margin of 8.02% and a return on equity of 18.08%. As a group, analysts forecast that GSK plc will post 175.980975 earnings per share for the current year.
Insider Buying and Selling
In other GSK news, insider Jonathan Symonds bought 1,500 shares of GSK stock in a transaction dated Friday, December 20th. The stock was acquired at an average cost of GBX 1,315 ($17.05) per share, for a total transaction of £19,725 ($25,580.34). Also, insider Emma Walmsley sold 120,653 shares of the firm's stock in a transaction dated Monday, February 10th. The stock was sold at an average price of GBX 1,453 ($18.84), for a total transaction of £1,753,088.09 ($2,273,489.94). 1.61% of the stock is currently owned by insiders.
About GSK
(
Get Free Report)
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider GSK, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GSK wasn't on the list.
While GSK currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
